HU229319B1 - Cathartic composition - Google Patents

Cathartic composition Download PDF

Info

Publication number
HU229319B1
HU229319B1 HU0302422A HUP0302422A HU229319B1 HU 229319 B1 HU229319 B1 HU 229319B1 HU 0302422 A HU0302422 A HU 0302422A HU P0302422 A HUP0302422 A HU P0302422A HU 229319 B1 HU229319 B1 HU 229319B1
Authority
HU
Hungary
Prior art keywords
pond
lake
diarrhea
compound
taken
Prior art date
Application number
HU0302422A
Other languages
English (en)
Hungarian (hu)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24630250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU229319(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of HUP0302422A2 publication Critical patent/HUP0302422A2/hu
Publication of HUP0302422A3 publication Critical patent/HUP0302422A3/hu
Publication of HU229319B1 publication Critical patent/HU229319B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
HU0302422A 2000-09-05 2001-09-04 Cathartic composition HU229319B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/655,760 US6414016B1 (en) 2000-09-05 2000-09-05 Anti-constipation composition
PCT/JP2001/007628 WO2002020007A1 (en) 2000-09-05 2001-09-04 Cathartic composition

Publications (3)

Publication Number Publication Date
HUP0302422A2 HUP0302422A2 (hu) 2003-10-28
HUP0302422A3 HUP0302422A3 (en) 2005-02-28
HU229319B1 true HU229319B1 (en) 2013-10-28

Family

ID=24630250

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302422A HU229319B1 (en) 2000-09-05 2001-09-04 Cathartic composition

Country Status (25)

Country Link
US (7) US6414016B1 (enExample)
EP (2) EP1857105B1 (enExample)
JP (3) JP2004508327A (enExample)
KR (2) KR100901102B1 (enExample)
CN (1) CN100335049C (enExample)
AR (2) AR030609A1 (enExample)
AT (1) ATE476975T1 (enExample)
AU (2) AU8261501A (enExample)
BR (1) BRPI0114042B8 (enExample)
CA (1) CA2419741C (enExample)
CZ (1) CZ304740B6 (enExample)
DE (2) DE60142810D1 (enExample)
DK (2) DK1857105T3 (enExample)
ES (2) ES2347697T3 (enExample)
HU (1) HU229319B1 (enExample)
IL (2) IL154534A0 (enExample)
MX (1) MXPA03001959A (enExample)
NL (1) NL300757I2 (enExample)
NO (1) NO332701B1 (enExample)
NZ (1) NZ524401A (enExample)
PT (2) PT1315485E (enExample)
RU (1) RU2694361C3 (enExample)
TW (1) TWI305147B (enExample)
WO (1) WO2002020007A1 (enExample)
ZA (1) ZA200301673B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1220849E (pt) 1999-10-15 2004-10-29 Sucampo Ag Composicao de compostos biciclicos e metodo para a sua estabilizacao
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
US8114911B2 (en) * 2002-10-23 2012-02-14 Sucampo Ag Prostaglandin compounds for the treatment of obesity
ES2591252T3 (es) * 2002-12-27 2016-11-25 Sucampo Ag Derivados de prostaglandinas para tratar el síndrome de colon irritable y/o la dispepsia funcional
WO2005002588A1 (en) * 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
CN101048163A (zh) * 2004-09-02 2007-10-03 苏坎波公司 用于治疗胃肠道疾病的前列腺素衍生物
US8202909B2 (en) 2005-01-27 2012-06-19 Sucampo Ag Method for treating central nervous system disorders
CN103919783A (zh) * 2005-03-04 2014-07-16 苏坎波公司 治疗外周血管病的方法和组合物
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
BRPI0608818A2 (pt) * 2005-03-07 2010-01-26 Univ Chicago uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CN101198334B (zh) * 2005-04-12 2013-02-06 苏坎波公司 前列腺素化合物和质子泵抑制剂用于治疗肠胃病的联合应用
NZ570190A (en) 2006-01-24 2011-03-31 Sucampo Ag Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
EP2735566A1 (en) * 2006-02-07 2014-05-28 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
CA2742227C (en) * 2008-10-31 2017-01-24 Lipid Pharmaceuticals Ehf. The use of fatty acid compositions as laxatives
JP5502106B2 (ja) 2008-12-31 2014-05-28 アーデリクス，インコーポレーテッド 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるｎｈｅ媒介性アンチポートを阻害するための組成物および方法
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9382272B2 (en) 2009-01-22 2016-07-05 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
US8940790B2 (en) * 2009-11-03 2015-01-27 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
CA2784933A1 (en) * 2009-12-18 2011-06-23 Apotex Pharmachem Inc. Processes for the purification of lubiprostone
US8785663B2 (en) 2010-01-28 2014-07-22 Alfredo Paul Ceccarelli Polymorphic forms of Lubiprostone
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR102138390B1 (ko) 2012-08-21 2020-07-27 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료에서 ｎｈｅ-매개된 역수송 저해를 위한 화합물 및 방법
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR102287207B1 (ko) 2013-04-12 2021-08-09 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
AR105029A1 (es) * 2015-06-19 2017-08-30 Sucampo Ag Composición farmacéutica que comprende derivado de ácido graso
WO2018065826A1 (en) 2016-10-06 2018-04-12 Sucampo Ag Multilayer beads for pharmaceutical use
UA126283C2 (uk) 2017-01-09 2022-09-14 Арделікс, Інк. Сполуки, придатні для лікування розладів шлунково-кишкового тракту
CA3049679A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
JP6750733B2 (ja) * 2017-04-20 2020-09-02 株式会社島津製作所 分光光度計
US10422729B1 (en) 2019-03-08 2019-09-24 Biodesix, Inc. Blood sample separation devices and methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5720305B2 (enExample) 1973-02-28 1982-04-27
US4034003A (en) 1974-04-11 1977-07-05 Ono Pharmaceutical Co., Ltd. 15-Cycloalkyl-prostaglandins
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
JPS5391110A (en) 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
JPS6022708B2 (ja) 1977-07-14 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
US4308595A (en) * 1979-12-19 1981-12-29 International Business Machines Corporation Array driver
US4670569A (en) 1981-04-02 1987-06-02 G. D. Searle & Co. 5-fluoro-PGI2 compounds
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US4687864A (en) 1983-12-23 1987-08-18 G. D. Searle & Co. 5-fluoro-3-oxa-prostacyclin compounds
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
GB2210556B (en) 1987-10-02 1991-07-17 Ueno Seiyaku Oyo Kenkyujo Kk The use of 15-keto-16-halo-prostaglandins in cathartic compositions
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
JP2515442B2 (ja) * 1990-05-01 1996-07-10 株式会社上野製薬応用研究所 膵臓疾患処置剤
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
KR20010041696A (ko) 1998-03-11 2001-05-25 그레랑 파마수티컬 가부시키가이샤 발포성 장용(腸溶) 제제
US6471085B1 (en) 1999-10-04 2002-10-29 Anthony J. Gallo Temperature cup
PT1220849E (pt) * 1999-10-15 2004-10-29 Sucampo Ag Composicao de compostos biciclicos e metodo para a sua estabilizacao
ATE308606T1 (de) * 2000-07-14 2005-11-15 Henkel Kgaa Kompartiment-hohlkörper enthaltend wasch-, reinigungs- oder spülmittelportion
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition

Also Published As

Publication number Publication date
HUP0302422A3 (en) 2005-02-28
KR100901102B1 (ko) 2009-06-08
NZ524401A (en) 2004-08-27
EP1315485B1 (en) 2007-11-21
WO2002020007A1 (en) 2002-03-14
CN100335049C (zh) 2007-09-05
BRPI0114042B1 (pt) 2016-11-08
RU2694361C3 (ru) 2020-07-20
US6414016B1 (en) 2002-07-02
AU8261501A (en) 2002-03-22
DE60131547D1 (de) 2008-01-03
NO20030996L (no) 2003-05-02
US20050222195A1 (en) 2005-10-06
AR100291A2 (es) 2016-09-28
US20140235665A1 (en) 2014-08-21
ZA200301673B (en) 2003-11-26
US8071613B2 (en) 2011-12-06
ATE476975T1 (de) 2010-08-15
NL300757I1 (enExample) 2015-12-29
PT1857105E (pt) 2010-10-08
MXPA03001959A (es) 2003-06-24
CZ304740B6 (cs) 2014-09-17
DE60142810D1 (de) 2010-09-23
NO20030996D0 (no) 2003-03-04
JP2009286806A (ja) 2009-12-10
DK1315485T3 (da) 2008-03-03
EP1857105A2 (en) 2007-11-21
JP4684334B2 (ja) 2011-05-18
KR20080091278A (ko) 2008-10-09
DE60131547T2 (de) 2008-10-23
JP2009114217A (ja) 2009-05-28
US20120237598A1 (en) 2012-09-20
BR0114042A (pt) 2003-07-22
EP1857105B1 (en) 2010-08-11
BRPI0114042B8 (pt) 2021-05-25
DK1857105T3 (da) 2010-09-20
CA2419741A1 (en) 2002-03-14
ES2296786T3 (es) 2008-05-01
US20030216465A1 (en) 2003-11-20
AR030609A1 (es) 2003-08-27
EP1315485A1 (en) 2003-06-04
EP1857105A3 (en) 2008-03-05
NO332701B1 (no) 2012-12-10
JP2004508327A (ja) 2004-03-18
US20030040528A1 (en) 2003-02-27
KR100918223B1 (ko) 2009-09-21
RU2694361C2 (ru) 2019-07-12
AU2001282615B2 (en) 2006-06-22
ES2347697T3 (es) 2010-11-03
HUP0302422A2 (hu) 2003-10-28
KR20030029919A (ko) 2003-04-16
US6610732B2 (en) 2003-08-26
NL300757I2 (enExample) 2015-12-29
TWI305147B (en) 2009-01-11
CA2419741C (en) 2010-11-30
US20120022152A1 (en) 2012-01-26
US8748454B2 (en) 2014-06-10
CN1655776A (zh) 2005-08-17
PT1315485E (pt) 2008-01-23
US8114890B1 (en) 2012-02-14
RU2694361C9 (ru) 2019-12-25
IL154534A (en) 2010-04-29
IL154534A0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
HU229319B1 (en) Cathartic composition
ES2938560T3 (es) Formulaciones de cannabinoides estables
DE69611369T2 (de) Sublingual oder bukkal verabreichte arzneistoffe mit gesteuerter freisetzung
US10342797B2 (en) Solubility of therapeutic agents
ES2261523T3 (es) Inhibidores de farnesil proteina transferasa para el tratamiento de enfermedad intestinal inflamatoria.
PT1158959E (pt) Composições e métodos para a administração melhorada de agentes terapêuticos hidrófobos
BRPI0614484A2 (pt) extrato de scf contendo glicose cardìaca
LU87560A1 (fr) Composition pharmaceutique intraveineuse et procede pour sa preparation
HUE027395T2 (hu) Eszközök nyálkahártyán keresztül történõ bejuttatására, javított felszívódással
KR20080092373A (ko) 치료용 조성물
Wright et al. Intra-Articular Therapy in Osteo-Arthritis: Comparison of Hydrocortisone Acetate and Hydro-Cortisone
JP2013534930A (ja) 糖尿病を治療するための多成分調剤
EP0306422A1 (fr) Nouvelles formes galéniques de béta-2-mimétiques pour administration par voie per- et sublinguale
DE69835824T2 (de) Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
DE68903814T2 (de) Etoposid-loesungen.
AU664174B2 (en) Dry starch-iodine pharmaceutical formulations
DD267187A5 (de) Verfahren zur herstellung von mitteln zur bekaempfung des asthma bronchiale und der chonisch obstruktiven bronchitis
US20090182041A1 (en) Control of cancer with annonaceous extracts
US5955101A (en) Dry starch-iodine pharmaceutical formulations
DE69529819T2 (de) Neue kombination eines betablockers mit einem lokalanästhetikum
US5910318A (en) Treatment of iodine deficiency diseases
HU217431B (hu) Ipriflavont tartalmazó gyógyászati készítmények, és eljárás ezek előállítására
JP2024501764A (ja) 併用療法
ES2882578T3 (es) Formulaciones antibióticas inyectables y uso de las mismas
JP4493018B2 (ja) 平滑筋蠕動抑制剤